Abstract: The present invention relates to compounds of formula I, or pharmaceutically acceptable salts thereof, as well as compositions comprising such compounds. These compounds and compositions have uses in the treatment of psychiatric or neurological disorders. Compounds of formula I comprise at least one deuterium atom at the ?-position and consequently have improved oral bioavailability relative to ?-diprotic analogues.

Abstract: A method for preparing 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) is provided which starts from 5-methoxy-1H-indole. The product obtained can be purified via formation of a salt, such as a fumarate salt, of 5-MeO-DMT.

Abstract: Syntheses of compounds of Formula III from compounds of Formula I via compounds of Formula II are described, as well as particular compounds of Formula III, or pharmaceutically acceptable salts thereof, compositions comprising such compounds, and uses thereof. For example, certain of these compounds and compositions of Formula III have uses in the treatment of psychiatric or neurological disorders.

Abstract: The invention provides a novel synthetic route for the preparation of the Chk-1 inhibitor compound: as well as novel process intermediates per se.

Abstract: Syntheses of compounds of Formula Ill from compounds of Formula I via compounds of Formula II are described, as well as particular compounds of Formula III, or pharmaceutically acceptable salts thereof, compositions comprising such compounds, and uses thereof. For example, certain of these compounds and compositions of Formula III have uses in the treatment of psychiatric or neurological disorders.

Abstract: Syntheses of compounds of Formula III from compounds of Formula I via compounds of Formula II are described, as well as particular compounds of Formula III, or pharmaceutically acceptable salts thereof, compositions comprising such compounds, and uses thereof. For example, certain of these compounds and compositions of Formula III have uses in the treatment of psychiatric or neurological disorders.

Abstract: The present invention relates to compounds of formula I, or pharmaceutically acceptable salts thereof, as well as compositions comprising such compounds. These compounds and compositions have uses in the treatment of psychiatric or neurological disorders. Compounds of formula I comprise at least one deuterium atom at the ?-position and consequently have improved oral bioavailability relative to ?-diprotic analogues.

Abstract: Syntheses of compounds of Formula III from compounds of Formula I via compounds of Formula II are described, as well as particular compounds of Formula III, or pharmaceutically acceptable salts thereof, compositions comprising such compounds, and uses thereof. For example, certain of these compounds and compositions of Formula III have uses in the treatment of psychiatric or neurological disorders.

Abstract: A process and intermediates for making the compound of Formula (I).

Abstract: The present invention relates to compounds of formula I, or pharmaceutically acceptable salts thereof, as well as compositions comprising such compounds. These compounds and compositions have uses in the treatment of psychiatric or neurological disorders. Compounds of formula I comprise at least one deuterium atom at the ?-position and consequently have improved oral bioavailability relative to ?-diprotic analogues.

Abstract: The present invention relates to compounds of formula I, or pharmaceutically acceptable salts thereof, as well as compositions comprising such compounds. These compounds and compositions have uses in the treatment of psychiatric or neurological disorders. Compounds of formula I comprise at least one deuterium atom at the ?-position and consequently have improved oral bioavailability relative to ?-diprotic analogues.

Abstract: Syntheses of compounds of Formula III from compounds of Formula I via compounds of Formula II are described, as well as particular compounds of Formula III, or pharmaceutically acceptable salts thereof, compositions comprising such compounds, and uses thereof. For example, certain of these compounds and compositions of Formula III have uses in the treatment of psychiatric or neurological disorders.

Abstract: A door packing assembly can include a pallet having a plurality of frames positioned thereon. The plurality of frames define an interior area, and a plurality of doors are positioned onto the pallet within the interior area defined by the plurality of frames. In further instances, a door container component can be positioned onto the pallet and the plurality of doors can be positioned within the door container component. In this way, the door container component can have a perimeter surrounded by at least some of the plurality of frames.

Abstract: Embodiments of devices, assemblies, and related methods for transporting glass panels, such as doors, are disclosed. One embodiment of a rack assembly includes a support rack and a first support wedge positioned at the support rack. The first support wedge includes a first end and a second end opposite the first end. The first support wedge further includes a first surface extending between the first end and the second end as well as a second surface extending between the first end and the second end opposite the first surface. The second surface defines a plurality of support platform pairs. Each support platform pair includes a first platform at a first elevation relative to the first surface and a second platform at a second elevation relative to the first surface. The second elevation is different than the first elevation.

Abstract: Embodiments of devices, assemblies, and related methods for transporting glass panels, such as doors, are disclosed. One embodiment of a rack assembly includes a support rack and a first support wedge positioned at the support rack. The first support wedge includes a first end and a second end opposite the first end. The first support wedge further includes a first surface extending between the first end and the second end as well as a second surface extending between the first end and the second end opposite the first surface. The second surface defines a plurality of support platform pairs. Each support platform pair includes a first platform at a first elevation relative to the first surface and a second platform at a second elevation relative to the first surface. The second elevation is different than the first elevation.

Abstract: The present invention pertains generally to the field of organic chemical synthesis, and in particular to certain methods for the synthesis of 8-(4-aminophenyoxy)-4H-pyrido[2,3-b]pyrazin-3-one and related compounds (denoted herein as (3)) from 4-(4-aminophenyoxy)pyridine-2,3-diamine and related compounds (denoted herein as (1)), by reaction with glyoxylic acid (denoted herein as (2)). The compounds (3) are useful in the synthesis of known anti-cancer agents, such as 1-(5-tert-butyl-2-(4-methyl-phenyl)-pyrazol-3-yl)-3-[2-fluoro-4-[(3-oxo-4H-pyrido[2,3-b]pyrazin-8-yl)oxy]phenyl]urea.

Abstract: Door, frame, and door and frame assembly embodiments are disclosed herein. The disclosed embodiments can provide one or more useful insulating features in a variety of applications. One embodiment of a door includes a glass unit and a rail assembly receiving the glass unit. The rail assembly can include a first body having a first sidewall and a first insulating member secured to the first sidewall. The first insulating member can have a first wall and a second wall spaced from the first wall by a first support and a second support. The first wall, the second wall, the first support, and the second support can define a first cavity of the first insulating member.

Abstract: The present invention pertains generally to the field of organic chemical synthesis, and in particular to certain methods for the synthesis of 8-(4-aminophenyoxy)-4H-pyrido[2,3-b[pyrazin-3-one and related compounds (denoted herein as (3)) from 4-(4-aminophenyoxy)pyridine-2,3-diamine and related compounds (denoted herein as (1)), by reaction with glyoxylic acid (denoted herein as (2)). The compounds (3) are useful in the synthesis of known anti-cancer agents, such as 1-(5-tert-butyl-2-(4-methyl-phenyl)-pyrazol-3-yl)-3-[2-fluoro-4-[(3-oxo-4H-pyrido[2,3-b]pyrazin-8-yl)oxy]phenyflurea.